LN-6: a monoclonal antibody to vimentin expressed in non-hematopoietic mesenchymal cells and derived tumors and reactive in B5-fixed, paraffin-embedded tissues. | Zendy

E Stathopoulos | Zendy; Gregory S. Naeve | Zendy; C. R. Taylor | Zendy; Alan L. Epstein | Zendy

Open Access

LN-6: a monoclonal antibody to vimentin expressed in non-hematopoietic mesenchymal cells and derived tumors and reactive in B5-fixed, paraffin-embedded tissues.

Author(s) -

E Stathopoulos,

Gregory S. Naeve,

C. R. Taylor,

Alan L. Epstein

Publication year - 1989

Publication title -

journal of histochemistry and cytochemistry

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.971

H-Index - 124

eISSN - 1551-5044

pISSN - 0022-1554

DOI - 10.1177/37.9.2671152

Subject(s) - vimentin , monoclonal antibody , immunohistochemistry , mesenchymal stem cell , pathology , chemistry , microbiology and biotechnology , antibody , stain , haematopoiesis , biology , cancer research , staining , immunology , medicine , stem cell

We generated a monoclonal antibody (MAb), designated LN-6, directed against human vimentin, which retains its immunoreactivity in B5-fixed, paraffin-embedded tissues. Like other anti-vimentin MAb, LN-6 was found to be reactive with a wide spectrum of human sarcomas and normal cells of mesenchymal derivation. However, unlike other similar reagents, LN-6 was unreactive with normal and malignant human lymphoid cells and therefore displays a more restricted immunoreactivity. Because of its ability to stain routinely processed pathological tissues and its marked reactivity with human sarcomas, LN-6 is a unique reagent for the immunohistochemical diagnosis of human cancer.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research